AI 기반 Drug Discovery 시장 예측(-2034년) : 제품별, 기술별, 용도별, 약제 종류별, 치료 분야별, 최종사용자별, 지역별 세계 분석

According to Stratistics MRC, the Global AI-Driven Drug Discovery Market is accounted for $10.5 billion in 2026 and is expected to reach $21.5 billion by 2034 growing at a CAGR of 9.3% during the forecast period. AI-driven drug discovery refers to the application of computational algorithms and machine learning models to identify, design, and optimize novel therapeutic compounds. It functions by analyzing vast biological datasets to predict molecular interactions, toxicity, and efficacy, thereby accelerating the identification of viable drug candidates. These systems utilize deep learning, natural language processing, and generative models to streamline target validation and lead optimization. This approach significantly reduces the time and cost associated with traditional pharmaceutical research and development pipelines.

Market Dynamics:

Driver:

Rising Pharmaceutical R&D Costs

The escalating costs of traditional pharmaceutical research compel companies to adopt AI-driven discovery platforms offering efficient compound identification alternatives. Growing complexity in target validation and high failure rates in clinical trials are accelerating the integration of these computational tools into drug development frameworks. This transition is supported by advancements in machine learning, which enhance predictive accuracy. Consequently, pharmaceutical firms are investing in AI technologies to achieve compliance with efficiency benchmarks while optimizing overall R&D expenditures.

Restraint:

Data Quality and Integration Challenges

The substantial difficulties associated with aggregating and standardizing diverse biological datasets represent a significant barrier to widespread commercial adoption. Developing highly accurate predictive models often requires complex data cleaning processes and sophisticated integration techniques, which escalate overall development costs. Furthermore, the variability in data formats limits the operational reliability of generalized AI algorithms. These factors collectively constrain market expansion, particularly for smaller enterprises with limited data infrastructure budgets.

Opportunity:

Expansion in Generative AI Molecule Design

The generative AI sector presents substantial growth opportunities for drug discovery platform providers due to increasing demand for novel compound creation. Advanced generative models offer a highly effective pathway to design unique molecular structures without relying on existing libraries, utilizing deep learning algorithms as primary inputs. As global investments in computational chemistry expand, the adoption of advanced generative AI solutions is expected to surge significantly.

Threat:

Competition from Traditional High-Throughput Screening

The continuous reliance on traditional high-throughput screening methodologies poses a considerable threat to the AI-driven drug discovery market. Conventional physical screening assays and established robotic platforms often exhibit superior regulatory familiarity and can be more economically viable for facilities with existing infrastructure. Additionally, the rapid advancement of automated screening technologies is enhancing the efficiency of conventional discovery methods. This competitive pressure may hinder market penetration.

Covid-19 Impact:

The pandemic initially disrupted laboratory operations and delayed clinical trials due to facility closures. However, the subsequent need for rapid therapeutic development accelerated the adoption of AI-driven discovery platforms for virtual screening and compound optimization. Post-pandemic, the heightened focus on pandemic preparedness and accelerated drug development has reinforced long-term investments in AI technologies, driving robust market recovery and expansion across diverse pharmaceutical sectors globally.

The software segment is expected to be the largest during the forecast period

The software segment is expected to account for the largest market share during the forecast period, due to its foundational role and widespread applicability across diverse pharmaceutical research environments. Software platforms offer exceptional computational scalability and operate effectively in analyzing massive biological datasets, which significantly reduces discovery timelines and minimizes manual intervention in daily research processes. As industries increasingly prioritize efficient drug development methods, the demand for specialized AI software continues to surge, thereby solidifying its dominant market position.

The generative AI segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the generative AI segment is predicted to witness the highest growth rate, driven by rapid advancements in deep learning architectures and molecular design engineering. These technologies enable the precise creation of novel compounds to produce highly specialized and robust therapeutic outputs tailored for specific disease applications. The ability to enhance discovery speed, operational scalability, and molecular diversity through advanced generative integration significantly improves process economics, accelerating commercial adoption globally.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to the presence of well-established pharmaceutical industries and advanced computational infrastructure that heavily utilize AI-driven drug discovery. The region benefits from substantial research and development investments, robust intellectual property protection, and supportive government initiatives promoting technological innovation in healthcare. Furthermore, the early adoption of advanced AI platforms by key industry players in the United States and Canada reinforces the region's dominant position globally.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapid pharmaceutical modernization and expanding biotechnology sectors in emerging economies. Countries such as China, India, and Japan are increasingly investing in computational infrastructure and AI-driven research technologies to meet growing domestic healthcare demands and stringent efficiency regulations. Additionally, favorable government policies, rising foreign direct investment, and the availability of cost-effective technological resources are collectively driving the accelerated adoption of AI drug discovery across the region.

Key players in the market

Some of the key players in AI-Driven Drug Discovery Market include Schrodinger, Inc., Recursion Pharmaceuticals, Inc., Exscientia plc, Insilico Medicine, Tempus AI, Inc., Relay Therapeutics, Inc., Absci Corporation, Owkin, Inc., Structure Therapeutics Inc., NVIDIA Corporation, International Business Machines Corporation, Microsoft Corporation, Alphabet Inc., Amazon.com, Inc., Dassault Systemes SE, Merck KGaA, Illumina, Inc., and AbCellera Biologics Inc.

Key Developments:

In September 2026, Schrodinger, Inc. launched a next-generation generative AI platform optimized for novel molecule design, achieving a thirty percent improvement in compound viability while significantly reducing computational time requirements for global pharmaceutical researchers.

In August 2026, Recursion Pharmaceuticals, Inc. expanded its automated biology capacity through a strategic partnership with a leading tech firm, enabling the scalable deployment of novel phenotypic screening modules for drug discovery.

In July 2026, Exscientia plc secured a major supply agreement to provide customized AI-driven drug design services for a prominent biotech company, facilitating the efficient integration of advanced computational tools into next-generation therapeutic ecosystems globally.

Offerings Covered:

• Software
• Services
• AI Drug Discovery Platforms
• AI Drug Discovery Engines
• Cloud-Based Drug Discovery Solutions
• AI-Enabled Drug Discovery Consulting Services
• Integrated AI Drug Discovery Solutions

Technologies Covered:

• Machine Learning
• Deep Learning
• Natural Language Processing
• Computer Vision
• Generative AI
• Knowledge Graphs and Graph Neural Networks

Applications Covered:

• Target Identification and Validation
• Virtual Screening and Molecule Screening
• De Novo Drug Design
• Lead Discovery and Optimization
• Drug Repurposing
• Preclinical Testing and Prediction
• Biomarker Discovery

Drug Types Covered:

• Small Molecules
• Biologics
• Antibodies
• Peptides and Proteins
• Nucleic Acid-Based Therapeutics
• Cell and Gene Therapies
• Other Drug Types

Therapeutic Areas Covered:

• Oncology
• Neurodegenerative Diseases
• Cardiovascular Diseases
• Metabolic Diseases
• Infectious Diseases
• Immunological Diseases
• Rare Diseases
• Respiratory Diseases
• Other Therapeutic Areas

End Users Covered:

• Pharmaceutical Companies
• Biotechnology Companies
• Contract Research Organizations
• Contract Development and Manufacturing Organizations
• Academic and Research Institutes
• Government Research Organizations
• Other End Users

Regions Covered:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Sweden
  • Switzerland
  • Poland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Vietnam
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America
• Rest of the World (RoW)
  • Middle East
• Saudi Arabia
• United Arab Emirates
• Qatar
• Israel
• Rest of Middle East
  • Africa
• South Africa
• Egypt
• Morocco
• Rest of Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

• 1.1 Market Snapshot and Key Highlights
• 1.2 Growth Drivers, Challenges, and Opportunities
• 1.3 Competitive Landscape Overview
• 1.4 Strategic Insights and Recommendations

2 Research Framework

• 2.1 Study Objectives and Scope
• 2.2 Stakeholder Analysis
• 2.3 Research Assumptions and Limitations
• 2.4 Research Methodology
  • 2.4.1 Data Collection (Primary and Secondary)
  • 2.4.2 Data Modeling and Estimation Techniques
  • 2.4.3 Data Validation and Triangulation
  • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

• 3.1 Market Definition and Structure
• 3.2 Key Market Drivers
• 3.3 Market Restraints and Challenges
• 3.4 Growth Opportunities and Investment Hotspots
• 3.5 Industry Threats and Risk Assessment
• 3.6 Technology and Innovation Landscape
• 3.7 Emerging and High-Growth Markets
• 3.8 Regulatory and Policy Environment
• 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

• 4.1 Porter's Five Forces Analysis
  • 4.1.1 Supplier Bargaining Power
  • 4.1.2 Buyer Bargaining Power
  • 4.1.3 Threat of Substitutes
  • 4.1.4 Threat of New Entrants
  • 4.1.5 Competitive Rivalry
• 4.2 Market Share Analysis of Key Players
• 4.3 Product Benchmarking and Performance Comparison

5 Global AI-Driven Drug Discovery Market, By Offering

• 5.1 Software
• 5.2 Services
• 5.3 AI Drug Discovery Platforms
• 5.4 AI Drug Discovery Engines
• 5.5 Cloud-Based Drug Discovery Solutions
• 5.6 AI-Enabled Drug Discovery Consulting Services
• 5.7 Integrated AI Drug Discovery Solutions

6 Global AI-Driven Drug Discovery Market, By Technology

• 6.1 Machine Learning
• 6.2 Deep Learning
• 6.3 Natural Language Processing
• 6.4 Computer Vision
• 6.5 Generative AI
• 6.6 Knowledge Graphs and Graph Neural Networks

7 Global AI-Driven Drug Discovery Market, By Application

• 7.1 Target Identification and Validation
• 7.2 Virtual Screening and Molecule Screening
• 7.3 De Novo Drug Design
• 7.4 Lead Discovery and Optimization
• 7.5 Drug Repurposing
• 7.6 Preclinical Testing and Prediction
• 7.7 Biomarker Discovery

8 Global AI-Driven Drug Discovery Market, By Drug Type

• 8.1 Small Molecules
• 8.2 Biologics
• 8.3 Antibodies
• 8.4 Peptides and Proteins
• 8.5 Nucleic Acid-Based Therapeutics
• 8.6 Cell and Gene Therapies
• 8.7 Other Drug Types

9 Global AI-Driven Drug Discovery Market, By Therapeutic Area

• 9.1 Oncology
• 9.2 Neurodegenerative Diseases
• 9.3 Cardiovascular Diseases
• 9.4 Metabolic Diseases
• 9.5 Infectious Diseases
• 9.6 Immunological Diseases
• 9.7 Rare Diseases
• 9.8 Respiratory Diseases
• 9.9 Other Therapeutic Areas

10 Global AI-Driven Drug Discovery Market, By End User

• 10.1 Pharmaceutical Companies
• 10.2 Biotechnology Companies
• 10.3 Contract Research Organizations
• 10.4 Contract Development and Manufacturing Organizations
• 10.5 Academic and Research Institutes
• 10.6 Government Research Organizations
• 10.7 Other End Users

11 Global AI-Driven Drug Discovery Market, By Geography

• 11.1 North America
  • 11.1.1 United States
  • 11.1.2 Canada
  • 11.1.3 Mexico
• 11.2 Europe
  • 11.2.1 United Kingdom
  • 11.2.2 Germany
  • 11.2.3 France
  • 11.2.4 Italy
  • 11.2.5 Spain
  • 11.2.6 Netherlands
  • 11.2.7 Belgium
  • 11.2.8 Sweden
  • 11.2.9 Switzerland
  • 11.2.10 Poland
  • 11.2.11 Rest of Europe
• 11.3 Asia Pacific
  • 11.3.1 China
  • 11.3.2 Japan
  • 11.3.3 India
  • 11.3.4 South Korea
  • 11.3.5 Australia
  • 11.3.6 Indonesia
  • 11.3.7 Thailand
  • 11.3.8 Malaysia
  • 11.3.9 Singapore
  • 11.3.10 Vietnam
  • 11.3.11 Rest of Asia Pacific
• 11.4 South America
  • 11.4.1 Brazil
  • 11.4.2 Argentina
  • 11.4.3 Colombia
  • 11.4.4 Chile
  • 11.4.5 Peru
  • 11.4.6 Rest of South America
• 11.5 Rest of the World (RoW)
  • 11.5.1 Middle East
    • 11.5.1.1 Saudi Arabia
    • 11.5.1.2 United Arab Emirates
    • 11.5.1.3 Qatar
    • 11.5.1.4 Israel
    • 11.5.1.5 Rest of Middle East
  • 11.5.2 Africa
    • 11.5.2.1 South Africa
    • 11.5.2.2 Egypt
    • 11.5.2.3 Morocco
    • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

• 12.1 Industry Value Network and Supply Chain Assessment
• 12.2 White-Space and Opportunity Mapping
• 12.3 Product Evolution and Market Life Cycle Analysis
• 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

• 13.1 Mergers and Acquisitions
• 13.2 Partnerships, Alliances, and Joint Ventures
• 13.3 New Product Launches and Certifications
• 13.4 Capacity Expansion and Investments
• 13.5 Other Strategic Initiatives

14 Company Profiles

• 14.1 Schrodinger, Inc.
• 14.2 Recursion Pharmaceuticals, Inc.
• 14.3 Exscientia plc
• 14.4 Insilico Medicine
• 14.5 Tempus AI, Inc.
• 14.6 Relay Therapeutics, Inc.
• 14.7 Absci Corporation
• 14.8 Owkin, Inc.
• 14.9 Structure Therapeutics Inc.
• 14.10 NVIDIA Corporation
• 14.11 International Business Machines Corporation
• 14.12 Microsoft Corporation
• 14.13 Alphabet Inc.
• 14.14 Amazon.com, Inc.
• 14.15 Dassault Systemes SE
• 14.16 Merck KGaA
• 14.17 Illumina, Inc.
• 14.18 AbCellera Biologics Inc.